Postmenopausal hormone therapy and atherosclerotic disease☆
References (60)
- et al.
Estrogen replacement therapy and coronary heart disease: a quantitiative assessment of the epidemiologic evidence
Prev Med
(1991) - et al.
Menopausal estrogen use, high density lipoprotein cholesterol subfractions and liver function
Atherosclerosis
(1983) - et al.
Lipid metabolic studies in oophorectomized women: effects on serum lipids and lipoproteins of three synthetic progestogens
Maturitas
(1982) - et al.
Effects of progestins on plasma lipoproteins and heparin-releasable lipases
Lipoprotein (a): an emerging risk factor for atherosclerosis
Can J Cardiol
(1989)Sex steroid hormone receptors in the cardiovascular system
Postgrad Med
(1989; April)- et al.
The effects of hormone replacement therapy in normal postmenopausal women: measurements of Doppler-derived parameters of aortic flow
Am J Obstet Gynecol
(1991) - et al.
Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause
Lancet
(1991) - et al.
Desogestrel- and levonorgestrel-containing oral contraceptives have different effects on urinary excretion of prostacyclin metabolites and serum high density lipoproteins
J Clin Endocrinol Metab
(1987) - et al.
Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women
Lancet
(1994)
Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits
J Clin Invest
(1991)
Wplyw leczenia estrogenami na niewydolnose wiencowa u kobiet po menopauzie
Pol Tyg Lek
(1971)
Estrogen replacement therapy, II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems
Obstet Gynecol
(1979)
A prospective study of postmenopausal estrogen therapy and coronary heart disease
N Engl J Med
(1985)
Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraceptive study
BMJ
(1989)
Coronary heart disease and its risk factors among women in the Framingham Study
Menopause and heart disease: a review
Ann NY Acad Sci
(1990)
Hormone therapy to prevent disease and prolong life in postmenopausal women
Ann Intern Med
(1992)
Effects of pharmacologic agents used, during menopause: impact on lipids and lipoproteins
Effects of conjugated equine estrogen with an without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoprotein A-1
Obstet Gynecol
(1991)
Effects of postmenopausal estrogen replacement on the concentration and metabolism of plasma lipoproteins
N Engl J Med
(1991)
High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies
Circulation
(1989)
The primary prevention of myocardial infarction
N Engl J Med
(1992)
A prospective one-year study of estrogen and progestin in postmenopausal women: effects on clinical symptoms and lipoprotein lipids
Obstet Gynecol
(1989)
Comparison of sequential versus continuous estrogen/progestin replacement therapy on serum lipid patterns: Multiuniversity National Upjohn Study Collaborative
Society for Gynecologic Investigation
(March 1991)
The effects of reproductive hormones on serum lipoproteins: unresolved issues in biology and clinical practice
Ann NY Acad Sci
(1990)
et al.The effects of reproductive hormones on serum lipoproteins: unresolved issues in biology and clinical practice
Ann NY Acad Sci
(1990)
Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women
N Engl J Med
(1993)
Postmenopausal estrogen use and heart disease risk factors in the 1980s: Rancho Bernardo, Calif., revisited
JAMA
(1989)
The effects of conjugated equine oestrogens with and without a cyclical progestin on lipoproteins and HDL subfractions in postmenopausal women
Acta Endocrinol (Cophenhagen)
(1986)
Efficacy of a continuous estrogen-progestin regimen in the menopausal patient
Obstet Gynecol
(1987)
Cited by (0)
- ☆
Supported by research grant No. HL 34594 from the National Institutes of Health.
- 1
Dr. Manson is a recipient of a Merck-Society for Epidemiologic Research Clinical Epidemiology Fellowship Award.
Copyright © 1994 Published by Mosby, Inc.